trial

Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.

NCTId NCT03164876
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 24 (actual)
Sponsored by Autifony Therapeutics Limited
Primary completion 2019-04-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-04-20
Primary completion
2019-04-03
Eligibility
MALE · 18 Years · 50 Years

Interventions & indications

Drugs
AUT00206

Sponsors

Autifony Therapeutics LimitedLead Sponsor
King's College LondonCollaborator

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
24
Phase
PHASE1
Primary Completion Date
2019-04-03
Status
COMPLETED
relationships
The graph out of here
drug
AUT00206
drug
lead_sponsor
Autifony Therapeutics Limited
company
collaborator
King's College London
company
indication
Schizophrenia
indication
Schizophrenia
indication